Proliferative Diabetic Retinopathy Market By Treatment Modality (Anti-VEGF Therapies, Laser Photocoagulation, Vitrectomy & Surgical Interventions, Steroid Injections); By Diagnostic Modality (Fundus Photography, Optical Coherence Tomography, Fluorescein Angiography, AI-Assisted Retinal Screening & Other Imaging Technologies); By End User (Ophthalmology & Retina Clinics, Hospitals, Ambulatory Surgical Centers, Diagnostic Imaging Centers, Primary Care & Community Screening Centers); By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa); Segment Revenue Estimation, Forecast, 2026–2032

Proliferative Diabetic Retinopathy Market: Screening Gaps and Recurring Retinal Therapy Shift Revenue Beyond One-Time Laser

The Global Proliferative Diabetic Retinopathy Market is projected to grow from USD 3.27 billion in 2025 to USD 5.64 billion by 2032, expanding at a robust CAGR of 8.12%, according to Strategic Market Research.

 

The market is moving from a predominantly laser-based treatment category toward a broader retinal-care ecosystem built around recurring anti-VEGF injections, advanced imaging, autonomous screening, long-duration drug delivery, and specialist surgery. Revenue growth is being supported by the expanding diabetes population, incomplete retinal-screening coverage, and the need to prevent abnormal retinal blood vessels from progressing to vitreous hemorrhage, retinal detachment, and permanent vision loss.

 

Proliferative diabetic retinopathy, or PDR, is the advanced stage of diabetic retinal disease. Its commercial importance is much greater than its share of the total diabetes population because confirmed PDR generally requires retina-specialist management, repeated monitoring, and active intervention. Treatment may involve panretinal photocoagulation, intravitreal anti-VEGF therapy, vitrectomy, or a combination of these approaches, depending on the presence of diabetic macular edema, bleeding, scar tissue, and retinal detachment.

 

Global modeling has estimated that in 2020, there were 103.12 million adults diagnosed with diabetic retinopathy, which includes 28.54 million individuals suffering from vision-threatening diabetic retinopathy. A prior disease-specific analysis approximated that around 17.2 million people worldwide have proliferative diabetic retinopathy (PDR). These statistics indicate a significant treatment demographic that encompasses screening, retinal imaging, consultations with specialists, injections, laser treatments, and surgical interventions.

 

Diabetes Expansion Enlarges the Long-Term Retinal-Care Pipeline

The future PDR treatment pool begins with the much larger diabetes population. The International Diabetes Federation estimated that 589 million adults aged 20–79 were living with diabetes in 2024, equivalent to approximately one in nine adults worldwide. More than four in ten were unaware that they had the condition, creating a sizeable detection gap that can delay both diabetes management and retinal screening.

PDR risk rises with longer diabetes duration, persistent hyperglycemia, hypertension, kidney disease, and other indicators of advanced metabolic burden. Longer survival with type 1 and type 2 diabetes leaves more patients exposed to retinal damage and progression into vision-threatening stages.

The United States reflects the scale of the broader care burden. In 2021, the Centers for Disease Control and Prevention estimated that 9.6 million people had diabetic retinopathy, including approximately 1.84 million with vision-threatening disease. This patient pool drives demand for advanced retinal assessment, monitoring, pharmacologic therapy, laser treatment, and surgical care.

Active PDR, PDR with diabetic macular edema, recurrent neovascularization, and complicated disease requiring surgery are the most commercially relevant patient groups. Each segment produces a different revenue pattern. PDR with macular edema supports repeated anti-VEGF administration, while high-risk disease without edema can favor durable laser treatment. Vitreous hemorrhage and tractional retinal detachment increase demand for operating-room procedures, surgical platforms, endolaser systems, and postoperative monitoring.

 

Screening Remains the Main Entry Point into Treatment

PDR can progress with limited warning before bleeding or retinal traction produces noticeable visual changes. Commercial demand therefore depends heavily on whether people with diabetes receive retinal examinations before irreversible damage develops. Screening determines how many patients move from an undiagnosed risk population into imaging, specialist consultation, pharmacological treatment, or laser intervention.

Only 66.0% of U.S. adults with diagnosed diabetes reported receiving an eye examination during the previous year in 2023. The remaining population represents a continuing gap in routine surveillance even in a market with developed ophthalmology infrastructure and established reimbursement pathways.

The screening gap is wider in lower-resource healthcare systems, where retinal cameras, trained graders, ophthalmologists, and referral networks are unevenly distributed. High-income countries produce greater treatment revenue per diagnosed patient, while lower- and middle-income countries contain larger undertreated populations.

Retinal imaging is increasingly being utilized as a tool for market access. Fundus cameras, wide-field imaging, optical coherence tomography, and tele-retinal networks are facilitating assessments within primary care clinics, diabetes centers, and community programs. Optical coherence tomography (OCT) is capable of detecting concurrent diabetic macular edema, which may influence treatment choices and lead to a rise in the repeated use of anti-VEGF therapies.

Within the diagnostic segment, fundus photography accounted for an estimated 39.2% share in 2025 because it supports large-scale screening and referral. OCT represented 37.8% and is forecast to grow at an 8.9% CAGR through 2032 as repeated monitoring expands. Fluorescein angiography held 15.4%, while AI-assisted and other retinal-screening technologies represented 7.6% and form the fastest-growing diagnostic subsegment at an estimated 13.4% CAGR.

Autonomous artificial-intelligence platforms are also reducing dependence on an eye specialist for the initial screening decision. Systems such as LumineticsCore and EyeArt can analyze retinal photographs and identify patients who require referral for advanced evaluation. These platforms expand the diagnosed population entering retina-specialist care and strengthen demand for follow-up imaging, injections, laser treatment, and surgery.

Commercial value depends on whether positive screens lead to completed specialist appointments through clear referral routes and reimbursed treatment.

 

Anti-VEGF Therapy Converts PDR into a Recurring-Care Market

Panretinal photocoagulation established the original commercial treatment model for PDR. Laser remains important because it can produce durable regression of abnormal vessels without requiring indefinite injections, and historical evidence supports its continued place in clinical guidelines.

Anti-VEGF treatment has changed the revenue structure by generating repeated injections, examinations, and imaging over several years. The DRCR Retina Network’s Protocol S established ranibizumab as a viable alternative to PRP, with five-year outcomes showing useful vision under both approaches but different treatment and follow-up requirements.

Eyes assigned to ranibizumab in Protocol S received an average of approximately 19 injections over five years. Patients assigned to PRP also received injections when diabetic macular edema required treatment, showing that the two revenue streams frequently overlap rather than operate as completely separate pathways.

Anti-VEGF therapy led the treatment market with a 50.8% share in 2025 and will expand at a 9.5% CAGR during 2026–2032. PRP represented 24.7% and is projected to grow at 5.8%, reflecting its established but less recurring revenue model. Vitrectomy and related surgical care accounted for 15.8% and are forecast to rise at 7.7%, while other supportive and monitoring services held 8.7% and are expected to expand at 6.5%.

Anti-VEGF therapy has particular commercial strength in PDR with diabetic macular edema. A single medicine can address macular leakage and retinal neovascular activity, making injection-based management more attractive than laser alone. Real-world Medicare evidence showed anti-VEGF treatment in 47.6% of beneficiaries with vision-threatening diabetic retinopathy plus macular edema, compared with 7.4% among those without macular edema. Laser use was 20.3% and 5.8%, respectively, demonstrating how the presence of edema changes treatment intensity and revenue mix.

PRP retains a strong position in PDR without macular edema, among patients unable to attend frequent appointments, and in health systems where the continuing cost of biologic therapy restricts access. Market competition therefore extends beyond clinical response. Payers and physicians also consider injection frequency, bilateral disease, travel requirements, drug acquisition costs, laser durability, and the consequences of interrupted follow-up.

 

Durability Becomes the Main Competitive Differentiator

Treatment burden is a major commercial pressure because each injection can require specialist examination, imaging, administration, and reassessment. Bilateral disease adds further pressure on clinic capacity and patient adherence.

Longer-acting products are addressing this burden. Eylea HD carries a diabetic-retinopathy dosing schedule that permits extended treatment intervals after initial monthly doses for suitable patients. This creates a competitive position based on fewer planned administrations rather than a completely different therapeutic pathway.

Roche’s Susvimo expanded the durability strategy into implant-based delivery. The refillable ocular implant received a U.S. diabetic-retinopathy indication in May 2025 for eligible patients who had previously responded to anti-VEGF injections. Its approximately nine-month refill interval can reduce administration frequency for selected patients while introducing surgical implantation, refill procedures, and device-related monitoring into the revenue model.

These products will be strongest among patients who respond to VEGF suppression but struggle with frequent appointments. Adoption will depend on payer coverage, physician confidence, surgical capacity, and whether fewer injections offset the complexity of longer-duration delivery.

 

Biosimilars Intensify Pricing and Formulary Competition

The expanding aflibercept biosimilar market is creating another competitive pressure. In May 2024, the FDA approved Yesafili and Opuviz as the first interchangeable biosimilars to Eylea for several retinal indications, including diabetic retinopathy. Pavblu and additional aflibercept biosimilars have also entered the regulatory landscape.

Biosimilars can broaden anti-VEGF access and strengthen payer control through preferred-product lists, step therapy, and negotiated reimbursement. Originator companies are responding through higher-dose formulations, longer intervals, and delivery systems that compete on durability rather than unit price.

Within anti-VEGF therapy, conventional branded biologics retained an estimated 72.5% share in 2025, while off-label and lower-cost agents represented 19.0% and biosimilars held 8.5%. Biosimilars are forecast to record the fastest subsegment CAGR of 18.6% through 2032, compared with 7.6% for conventional branded therapies, as formulary adoption and interchangeability broaden price-based competition.

The market is dividing into lower-cost anti-VEGF products, premium longer-interval biologics, and implant-based delivery, with evidence, contracting, and physician familiarity determining movement between tiers.

 

Complicated PDR Sustains High-Value Surgical Demand

Vitreoretinal surgery represents a smaller patient segment but a high-value portion of the market. Fragile new blood vessels can bleed into the vitreous, while scar tissue can pull on the retina and cause tractional detachment. These complications require surgical equipment, operating-room capacity, endolaser systems, tamponade agents, perioperative medicines, and extended postoperative monitoring.

The DRCR Retina Network’s Protocol AB compared aflibercept with vitrectomy plus PRP for PDR-related vitreous hemorrhage. Both pathways improved vision, but vitrectomy generally produced faster recovery and many patients eventually received both medical and surgical care.

Surgery functions as both an alternative and a rescue pathway. Anti-VEGF treatment may control bleeding or stabilize neovascular activity, but it cannot mechanically remove persistent hemorrhage or repair tractional retinal detachment. Hospitals and ambulatory surgical centers therefore retain commercial importance even as routine injections and laser sessions remain concentrated in outpatient retina practices.

 

Anti-VEGF Leads Treatment Revenue, While Retina Clinics Control Utilization

By treatment type, anti-VEGF therapy represents the strongest recurring pharmaceutical segment, supported by its 50.8% market share and 9.5% forecast CAGR. PDR with concurrent diabetic macular edema generates the highest injection intensity because both neovascular activity and macular swelling require control. PRP remains the leading durable intervention and maintains a strong position in resource-limited settings and among patients with unreliable follow-up. Vitrectomy accounts for fewer patients but produces greater spending per episode.

By diagnostic category, retinal imaging forms the largest recurring service layer. Fundus photography supports screening and referral, while OCT drives specialist monitoring and treatment decisions. Fluorescein angiography and wide-field imaging remain valuable for complex disease, while AI-assisted retinal screening is projected to grow faster than conventional imaging modalities.

By end user, ophthalmology and retina clinics held an estimated 58.6% share in 2025 and are forecast to grow at an 8.4% CAGR because they administer injections, perform laser procedures, and monitor disease activity. Hospitals and ambulatory surgery centers accounted for 27.4% and are projected to expand at 7.0%, capturing advanced surgical cases. Primary-care clinics, endocrinology practices, and community screening networks represented 14.0% and form the fastest-growing end-user segment at a 9.0% CAGR as autonomous imaging moves case detection beyond traditional eye-care settings.

 

North America Leads Revenue; Asia-Pacific Holds the Largest Expansion Opportunity

North America is positioned as the leading revenue region because of established retinal-specialist networks, anti-VEGF reimbursement, regular imaging use, and rapid access to new biologics, biosimilars, and ocular-delivery systems. Strategic Market Research estimates that North America accounted for 38.4% of global revenue in 2025 and will grow at a 7.5% CAGR through 2032. The United States also combines a large vision-threatening retinopathy population with strong clinical-trial infrastructure and advanced outpatient retina practices.

Europe held an estimated 27.2% share in 2025 and is projected to expand at a 6.8% CAGR. It remains a mature market for anti-VEGF therapy, laser systems, and vitreoretinal surgery. Biosimilar adoption may progress faster in cost-controlled European health systems, particularly where centralized purchasing supports switching from reference biologics.

Asia-Pacific accounted for approximately 25.8% of the 2025 market and is forecast to record the fastest regional CAGR of 10.2% during 2026–2032. The region contains a substantial share of the global diabetes population, but access to routine screening and retinal specialists differs widely between major cities and rural areas. India, China, and Southeast Asian countries are likely to generate growing demand for lower-cost imaging, tele-retinal screening, affordable anti-VEGF products, and durable laser treatment.

Latin America, the Middle East, and Africa collectively represented the remaining 8.6% share and are projected to grow at an 8.0% CAGR. Lower-income markets will remain more dependent on PRP and cost-sensitive biologics. Commercial expansion in these regions will rely on referral completion, specialist training, affordable treatment delivery, and wider reimbursement rather than equipment placement alone.

 

Competitive Positioning Extends Across the Entire Patient Pathway

Regeneron and Bayer compete through the Eylea franchise and extended-interval Eylea HD. Roche and Genentech participate through Lucentis and Susvimo, connecting conventional anti-VEGF therapy with implant-based delivery. Amgen, Samsung Bioepis, Biogen, and other biosimilar developers are increasing price competition around aflibercept.

Digital Diagnostics and Eyenuk participate earlier in the patient pathway through autonomous retinal-screening systems. Imaging companies, laser manufacturers, and vitreoretinal surgical-platform suppliers capture revenue after patients enter specialist care.

The strongest competitive positions combine treatment effectiveness, lower visit burden, payer coverage, and compatibility with retina-clinic workflows as care pathways increasingly combine imaging, injections, PRP, and surgery.

 

Market Outlook: Detection, Durability, and Access Will Decide Revenue Growth

The Proliferative Diabetic Retinopathy Market will be shaped by the conversion of undiagnosed diabetic-eye disease into treated specialist cases. Growth in the diabetes population provides the underlying patient base, while screening completion and referral access determine how much of that burden becomes commercial demand.

Anti-VEGF therapy will continue to lead pharmaceutical revenue because of repeat administration and its value in PDR with diabetic macular edema. Its 9.5% CAGR will remain above the overall market average, while biosimilars will grow faster from a smaller base. PRP will remain commercially durable because it reduces dependence on frequent follow-up and offers a practical treatment route in cost-sensitive markets. Vitrectomy will retain its high-value position for hemorrhage, retinal traction, and advanced structural complications.

Longer-acting biologics, refillable implants, and biosimilars will reshape competition during 2026–2032. Premium products will compete by reducing visit frequency, while biosimilars will compete through pricing and payer preference. Autonomous screening and tele-retinal networks will expand the top of the patient funnel, especially where ophthalmologist availability is limited.

Suppliers that connect early detection with affordable and durable treatment will hold the strongest strategic advantage. Revenue will increasingly favor companies that reduce missed diagnoses, lower treatment burden, and keep patients within long-term retinal-care pathways before bleeding, retinal detachment, or irreversible visual damage occurs.

 

Proliferative Diabetic Retinopathy Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 3.27 Billion
Revenue Forecast in 2032	USD 5.64 Billion
Overall Growth Rate	CAGR of 8.12% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Modality, By Diagnostic Modality, By End User, By Geography
By Treatment Modality	Anti-VEGF Therapies, Laser Photocoagulation, Vitrectomy & Surgical Interventions, Steroid Injections
By Diagnostic Modality	Fundus Photography, Optical Coherence Tomography, Fluorescein Angiography, AI-Assisted Retinal Screening & Other Imaging Technologies
By End User	Ophthalmology & Retina Clinics, Hospitals, Ambulatory Surgical Centers, Diagnostic Imaging Centers, Primary Care & Community Screening Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Market Drivers	Expanding global diabetes population and rising incidence of vision-threatening diabetic retinopathy Persistent retinal-screening and referral gaps that increase the pool of patients entering specialist treatment Growing use of recurring anti-VEGF therapies, advanced retinal imaging, and AI-assisted screening platforms
Customization Option	Available upon request